Robert Lasser, MD

Sage Therapeutics, Cambridge, Massachusetts

JCP
Long-Term Safety and Efficacy of Zuranolone in MDD
Original Research

December 27, 2023

Most patients with MDD achieved response after 14 days of zuranolone treatment. For patients who responded to their first treatment, the time to repeat treatment was over 4 months.
Andrew J. Cutler, Gregory W. Mattingly, Susan G. Kornstein, et al
JCP
Effect of Zuranolone vs Placebo in MDD
Original Research

February 20, 2023

This phase 3 RCT found significant improvement in depressive symptoms with zuranolone beginning at day 3 of treatment.
Anita H. Clayton, Robert Lasser, Indrani Nandy, et al
JCP
Effect of Zuranolone on Anxiety and Insomnia in Postpartum Depression
Original Research

January 30, 2023

Zuranolone was associated with improvements in depressive and anxiety symptoms and was beneficial for insomnia and patient-perceived functional health in patients with PPD.
Kristina M. Deligiannidis, Leslie Citrome, Ming-Yi Huang, et al
JCP
Original Research

August 15, 2013

Madhukar H. Trivedi, Andrew J. Cutler, Cynthia Richards, et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe